Zephyr
Biomanufacturing in Space
The future of drug manufacturing is off-planet
Microgravity is unlocking drug breakthroughs impossible on Earth. Zephyr is the first platform designed to scale bioproduction in space — and bring it safely back.
Why Conduct R&D in Space?
Space is rapidly becoming the next biomedical frontier.
In microgravity, biological systems behave in ways we can’t replicate on Earth. Cells grow differently, proteins form more precisely, and regenerative processes accelerate.
These effects create conditions that allow scientists to unlock new therapeutic pathways and refine existing treatments.
Opportunity and Impact of Experimental Drug Production in Space
Microgravity doesn’t just enhance research — it enables production.
Advanced biologics like monoclonal antibodies, stem-cell therapies, and synthetic compounds gain novel structures in space, potentially transforming how drugs are formulated and delivered.
Overcoming Earth’s Limits: The Case for Zephyr
Zephyr is an autonomous, reusable orbital lab designed to close the gap between scientific potential and operational reality.
Developed by Intuitive Machine with Rhodium Scientific and Space Forge, Zephyr enables low-cost missions to low-Earth orbit with soft landings near processing hubs.
For researchers, biotech companies, and forward-thinking investors, Zephyr represents a shift from one-off missions to repeatable, high-impact discovery and production cycles.

Igor Ciminelli
Founder of the School of Disruption & MD Titan

Dr. Heath Mills
Chief Scientific Officer at Rhodium Scientific. He has over 20 years experience leading international research efforts to characterize and understand life in extreme environments. In space-based research, he has been a Co-PI and PI on multiple projects funded by the NSF, NIH, DoD, NASA and CASIS.

Giuseppe Fedegari
President at Fedegari

Esther Deena
Materials engineer at Intuitive Machine